论文部分内容阅读
目的探讨吡柔比星与表阿霉素在乳腺癌化疗中不良反应的大小及其治疗作用、耐受性差异有无统计学意义。方法吡柔比星40~60 mg/m2加入糖水中静脉推注,表阿霉素75~90 mg/m2加入生理盐水中静脉推注,同时各加用剂量相等环磷酰胺、氟脲嘧啶。结果在胃肠道副反应、脱发方面,吡柔比星比表阿霉素的反应小,骨髓抑制吡柔比星比表阿霉素略明显或等同,心脏毒性、肝肾功能方面差异无统计学意义。结论两者的治疗作用差异无统计学意义,但吡柔比星不良反应相对轻,耐受性好,病人易接受。
Objective To investigate the effect of pirarubicin and epirubicin on breast cancer chemotherapy in patients with adverse reactions and their therapeutic effects, whether the differences were statistically significant. Methods Pirarubicin 40 ~ 60 mg / m2 was added to the syrup intravenously, epirubicin 75 ~ 90 mg / m2 intravenous injection of normal saline, while the same dose plus cyclophosphamide, fluorouracil. Results In gastrointestinal side effects and hair loss, the response of pirarubicin to epirubicin was small, and the myelosuppression of pirarubicin was slightly more or less than that of epirubicin. There was no statistical difference in cardiotoxicity and liver and kidney function Significance of learning. Conclusion There is no significant difference in therapeutic effect between the two groups, but the adverse reactions of pirarubicin are relatively light and well tolerated. Patients are easy to accept.